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Methods. A retrospective review was conducted on 400 randomly selected patients 
with SAB, 200 pre- and 200 post-implementation of a four-part management checklist. 
The primary outcome was overall adherence to the checklist, which included: repeat 
blood cultures, echocardiography, correct antibiotic/route selection, and appropriate 
antibiotic duration. Secondary outcomes included adherence when an ID physician was 
not consulted, adherence to the four components individually, and appropriate imaging.
Results. Adherence to the four part bundle remained stable from 2015 to 2017, 
with overall adherence rates of 80% and 79%, respectively. From 2015 to 2017, patients 
without repeat blood cultures (7% vs. 2%, respectively) and inappropriate inpatient 
antibiotic selection (6% vs. 3%, respectively) improved. Outpatient prescribing (11% 
vs. 11%), lack of imaging (11% vs. 9%), and antibiotic duration (15% vs. 15%) were 
consistent from 2015 to 2017, respectively. In 2017, 13 patients were discharged on oral 
antibiotics and were deemed inappropriate per the study criteria, although 12 of these 
patients were on appropriate antibiotics while inpatient. Infectious diseases providers 
were consulted on 96% of cases in 2017, an increase from 90% in 2015.
Conclusion. Adherence to an evidence based treatment bundle remains consistent 
with a previous analysis, despite an increase in cases with an ID provider consulted. 
Repeating blood cultures and inpatient prescribing improved over the interval. Focus 
areas for improvement include imaging, outpatient prescribing, and duration of therapy.
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Background. Vancomycin (VAN) combined with a β-lactam (COMBO) expe-
dites MRSA bacteremia clearance compared with VAN alone. However, the impact 
of COMBO on persistent MRSA bacteremia (PB) using a contemporary definition 
of ≥5 days is unknown. There is also no consensus on which β-lactam (BL) should 
be combined with VAN. We sought to assess PB rates among adults who received 
COMBO or VAN and the impact of BL class on PB.
Methods. This was an analysis of pooled data from two published studies 
of adults with MRSA bacteremia (Dilworth et  al., Antimicrob Agents Chemother. 
2014;58(1):102–109; Casapao et  al., Pharmacotherapy. 2017;37(11):1347–1356). All 
patients received intravenous VAN for ≥72 hours. COMBO patients received an intra-
venous BL for ≥48 hours with VAN, started within 24 hours of VAN. The remain-
ing patients comprised the VAN group. The primary outcome was PB (≥5 days). The 
impact of BL class on PB was assessed. Acute kidney injury (AKI, serum creatinine 
increase from baseline by 0.5 mg/dL or 50%) was examined as a secondary outcome. 
Demographics were compared between groups. Multivariable logistic regression mod-
els compared PB between COMBO and VAN.
Results. In total, 156 patients were included (VAN  =  66; COMBO  =  90). The 
groups were similar except COMBO patients were more likely to have a pulmonary 
bacteremia source (12.2% vs. 1.5%, P = 0.014) and a higher median (IQR) vancomycin 
serum level (mg/L, 17.8 (13.9, 23.6) vs. 15.7 (11.3, 20.6); P = 0.039). PB was less com-
mon in COMBO (26.7% vs. 43.9%, P = 0.027). In a multivariable model COMBO was 
inversely associated with PB (adjusted odds ratio [aOR], 95% confidence intervals [CI], 
0.48, 0.24–0.95). AKI was more common in COMBO (18.9% vs. 7.6%, P = 0.062). PB 
and AKI rates by BL class are shown in the table below, with VAN listed for reference.
Variable,  
n (%)
Carbapenem, 
n = 8
Cephalosporin, 
n = 25
Penicillin,  
n = 56 P-value
VAN,  
n = 66
PB 0 (0) 8 (32) 15 (26.8) 0.191 29 (43.9)
AKI 1 (12.5) 4 (16) 12 (21.4) 0.749 5 (7.6)
Conclusion. COMBO reduced the likelihood of PB but had a higher AKI rate. 
There were no significant differences in PB by BL class. Clinically, COMBO may reduce 
PB rates and prevent overuse of salvage antibiotic therapy. BL choice for COMBO war-
rants further investigation.
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Background. β-Lactam antibiotics are recommended as first line for treatment of 
methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia. The objective of this 
study was to compare effectiveness among β-lactam therapies in MSSA bacteremia 
patients that were exclusively treated with one antibiotic.
Methods. This was a retrospective cohort study of patients hospitalized at 
Veterans Affairs (VA) medical centers with MSSA bacteremia from January 1, 2002 to 
October 1, 2015. Patients were included if they were treated exclusively with nafcillin, 
oxacillin, cefazolin, or piperacillin/tazobactam (i.e., monotherapy with no changes in 
therapy). The primary outcome was 30-day mortality, and secondary outcomes were 
time to discharge, inpatient mortality, 30-day readmission, and 30-day S. aureus rein-
fection. Hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using 
unadjusted, quintile adjusted, and propensity-score (PS) matched (nearest neighbor, 
0.05 caliper) Cox proportional hazards regression.
Results. A total of 326 patients were included in the final analysis. When com-
paring nafcillin (n = 75)/oxacillin (n = 30) with cefazolin (n = 108), 30-day mortality 
was similar between groups (PS matched n = 40, HR 4.0, 95% CI 0.45–35.79), as were 
rates of the other outcomes assessed. When combining nafcillin/oxacillin with cefazo-
lin, and comparing to piperacillin/tazobactam (n = 113), 30-day mortality was signif-
icantly lower in the nafcillin/oxacillin/cefazolin group (PS matched n = 66, HR 0.29, 
95% CI 0.09–0.87). Inpatient mortality and 30-day mortality were significantly lower 
with nafcillin/oxacillin/cefazolin in PS-adjusted analyses (HR 0.29, 95% CI 0.11–0.73 
and HR 0.23, 95% CI 0.10–0.50, respectively).
Conclusion. In hospitalized patients with MSSA bacteremia, no difference in 
mortality was observed between nafcillin/oxacillin and cefazolin in patients that were 
exclusively treated with these monotherapies. However, higher mortality was observed 
with piperacillin/tazobactam as compared with nafcillin/oxacillin/cefazolin, suggest-
ing that it may not be as effective as other monotherapies for MSSA bacteremia.
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Background. Anti-staphylococcal penicillins (ASPs) have been regarded as first-
line in the treatment of serious MSSA bloodstream infections (BSI) with cefazolin con-
sidered an alternative. Recent studies have suggested that infection outcomes between 
cefazolin and ASPs may be similar. The objective of this study was to compare the 
clinical efficacy and tolerability of cefazolin to ASPs for MSSA BSI.
Methods. A  systematic review and meta-analysis was conducted. Articles were 
identified via PubMed, Web of Science, and the Cochrane Library. Studies written in 
English comparing cefazolin to ASPs for MSSA BSI in adult patients were included. 
Study quality was assessed using the Cochrane Risk of Bias Assessment Tool and the 
Newcastle-Ottawa Scale for prospective and retrospective studies, respectively. All 
review stages were independently conducted by two reviewers, with a third reviewer 
adjudicating any discrepancies. The fixed- or random-effects model was utilized, as 
appropriate. A planned subgroup analysis was conducted between high (>15%) vs. low 
(<14.9%) mortality probability as defined by logit functions applied at the study level.
Results. Nine studies were identified. Pooled data extracted from 1,726 cefazo-
lin- and 2,716 ASP-patients indicated that cefazolin was associated with a significant 
reduction in treatment failure (OR: 0.70; 95% CI: 0.61–0.82; P < 0.001; I2 = 14%) and 
crude, all-cause mortality (OR: 0.69; 95% CI: 0.59–0.81; P < 0.001; I2 = 18%) compared 
with ASPs. Within a subset of studies (n = 6) demonstrating low mortality probability 
(<14.9%), cefazolin therapy remained protective against failure (OR: 0.70; P < 0.001; 
I2  =  39%) and mortality (OR: 0.70; P < 0.001; I2  =  35%). Within the high mortality 
probability (>15%) subset, no significant differences for failure or mortality were noted. 
The risk of adverse events was higher with ASPs (OR: 2.58; 95% CI: 1.00–6.64; P = 0.05).
Conclusion. Cefazolin was associated with significantly lower rates of failure, 
mortality, and treatment-related adverse events when compared with ASPs among less 
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